Here are five things to know about the process, according to an Oct. 3 news release from CMS:
- Abbott formally requested the national coverage analysis in a 2023 letter.
- Transcatheter edge-to-edge repair (TEER) is used to treat mitral regurgitation. T-TEER applies similar technology to the treatment of tricuspid valve regurgitation.
- CMS is soliciting public comment, including scientific evidence and peer-reviewed literature, as part of the coverage analysis.
- The public comment period ends Nov. 2.
- CMS expects to complete its analysis by July 2.
